Company / SG&A Expense
GeneDx Holdings Corp. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$150.8M
FY2025
5-year range
$104.5M / $216.2M
FY2021-FY2025
Trend
+44.3%
vs FY2024
Sector context
#114 of 152
Health Care
What the data says
GeneDx Holdings Corp.'s sg&a expense of $151M is lower than 75% of companies in the Health Care sector (FY2025). SG&A Expense returned to growth in FY2025 after 2 years of decline, reaching $151M.
Based on SEC 10-K filings.
$151M in FY2025 with a 5-year CAGR of +8.4%.
Increased from $139M to $151M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -11.3%
- 5-Year CAGR
- +8.4%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 152This company $150.8M Sector average $182.7B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 44.3% year-over-year.
- Ranks #114 out of 152 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $150.8M | +44.3% |
| FY2024 | $104.5M | -24.8% |
| FY2023 | $139.0M | -35.7% |
| FY2022 | $216.2M | +4.9% |
| FY2021 | $206.0M | +104.5% |
| FY2020 | $100.7M | +241.7% |
| FY2019 | $29.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026